

BOOK EARLY AND
SAVE \$500

November 27-29, 2018 | Boston, MA



2nd Annual

Dermatology Drug Development Summit

Innovating & Accelerating the Development & Commercialization of Dermatology Drugs

25+ Expert Speakers Include:



Hans Hofland
VP – Research
& Nonclinical
Development
Dermira



Mandeep Kaur
VP & Head of North
America Medical
Affairs
Sanofi



Dogan Fidan
Head of Global Strategic
Franchise Immunology &
Inflammation
Galderma



Edward Hsia
VP, External
Research &
Innovation
Almirall



Paul Lizzul
CMO
**Sienna
Biopharmaceuticals**



Venkat Reddy
Senior VP & Global Head
of Translational Sciences
**Glenmark
Pharmaceuticals**

Partners



Tel: +1 617 455 4188 Email: info@hansonwade.com
www.dermatology-drugdevelopment.com



Welcome to the 2nd Annual Dermatology Drug Development Summit

Optimize efforts to develop and bring to market better and more efficient dermatological medicines

Undergoing tremendous therapeutic innovation, and targeting high unmet need, the dermatology space is thriving with opportunity to accelerate the development and bringing of better and more efficient therapies to market.

The **Dermatology Drug Development Summit** is the only industry-focused discussion and networking forum committed to addressing the key challenges to accelerate dermatology drug development and commercialization.

Join your peers to discover the latest insights on **how to accelerate preclinical and translational research, clinical development, approval and commercial activities of dermatological therapeutics**. Deepen your understanding of the latest approaches in formulation, drug delivery and topicals and developments in biological therapeutics targeting immunodermatological conditions.

Built with 20+ leaders including Sanofi, LEO Pharma and Dermira, sharing their learnings and case-studies, this meeting will leave you equipped with the knowledge and connections to advance your efforts at your own organization and benefit patients worldwide.

Great conference - very informative

Dermtech

Appreciate that the conference was well organized. Enjoyed the 'speed dating' time

Sonoma Pharmaceuticals

The Panel discussions were in general very inspiring especially due to the excellent preparation and facilitation

LEO Pharma

Key Highlights You Cannot Miss

- 1. LEO Pharma A/S and Sanofi** explore how to truly implement precision medicine approaches in dermatology drug development
- 2. Dermira** share their experience on how to de-risk topical product development
- 3. Concert Pharmaceuticals and Sienna Biopharmaceuticals** reveal more about the latest clinical data on their JAK Inhibitor candidates targeting alopecia areata, and atopic dermatitis and pruritus, respectively
- 4. Almirall** address the importance of external innovation as a key factor in the sustainability of dermatology R&D
- 5. Galderma** tackle the changing market dynamics, and the reimbursement and market access hurdles in dermatology
- 6. Glenmark Pharmaceuticals** discuss their latest results with a novel OX40 antagonistic mAb targeting atopic dermatitis
- 7. Cara Therapeutics Inc.** analyze how to achieve clinically meaningful endpoints in itch, and the validation of Patient-Reported Outcomes
- 8. FDA** share some regulatory perspectives on drug development in atopic dermatitis and alopecia areata, PROs and safety databases
- 9. Incyte Corporation** explore integrative preclinical research strategies to identify new therapeutic opportunities in dermatology
- 10. LEO Innovation Lab** focus on the growing possibilities of digitization in dermatology R&D including real-world evidence, digital tools and telemedicine

Expert Speaker Faculty



Conrad Winters
Director, Product
Development
CPL



Dan Piacquadio
President, CEO & Founder
Therapeutics Inc.



Dogan Fidan
Head of Global Strategic
Franchise Immunology &
Inflammation
Galderma



Edward Hsia
VP, External Research
& Innovation
Almirall



Frank Nestle
Global Head, Immunology
Therapeutic Research Area
& CSO North America
Sanofi



Frédérique Menzaghi
Senior VP, R&D
Cara Therapeutics, Inc.



Hans Hofland
VP – Research
& Nonclinical
Development
Dermira



Iain Stuart
Senior VP, R&D
**Foamix Pharmaceuticals,
Inc.**



James Cassella
Chief Development Officer
Concert Pharmaceuticals



Jean-Philippe Therrien
VP, Skin Biology
**EnDev Laboratories,
Tergus Pharma**



John Zibert
Medical Director &
CMO
LEO Innovation Lab



Jon Lenn
Senior VP, US
Operations
MedPharm



Kendall Marcus
Director, Division of
Dermatology & Dental
Products
FDA



Kim D. Kjøeller
Executive VP, Global R&D
LEO Pharma A/S



Lee Koetzner
Senior Manager, Preclinical
Pharmacology
**Castle Creek
Pharmaceuticals**



Mandeep Kaur
VP & Head of North
America Medical
Affairs
Sanofi



Mary Spellman
CMO
Menlo Therapeutics Inc



Michael Howell
Senior Director –
Translational Research
Incyte Corporation



Paul Lizzul
CMO
**Sienna
Biopharmaceuticals**



Paul Smith
Senior Director –
Preclinical Pharmacology
Incyte Corporation



Samir Mitragotri
Hiller Professor of
Bioengineering & Hansjorg
Wyss Professor of Biologically
Inspired Engineering
Harvard University



Venkat Reddy
Senior VP & Global Head
of Translational Sciences
**Glenmark
Pharmaceuticals**



Weston Daniel
Senior Director –
Program Manager
Excicure Inc.

Workshop Leaders



Betsy Hughes-Formella
Independent Consultant
Dermatology Drug
Development



Jasmina Jankicevic
Dermatologist,
Clinical Development
& Medical Affairs
Consulting



Robert Rissmann
Research Director
Dermatology
**Center for Human
Drug Research**



Vijendra Nalamothu
CEO
Tergus Pharma

💧 This meeting brings together the best scientists with
state of the art experience. Great job 💧
Bristol Myers Squibb, Past Attendee, Hanson Wade Event

Conference Day One | Wednesday, November 28, 2018

 Frank Nestle Sanofi  Hans Hofland Dermira  Kim D. Kjeller LEO Pharma A/S	8.15 Chair's Opening Remarks 8.30 Opening Keynote Panel Discussion: Innovating Dermatology Drug Development - Establishing the current landscape and state-of-the art in dermatology drug development – latest advances, study failures, and challenges - Analyzing the end-to-end pain points that accompany dermatology programs – from improving preclinical translation, to tackling late regulatory and commercial challenges - Identifying and addressing unmet needs – defining the strategic driver for companies involved in drug development for rare dermatological diseases or moderate skin conditions (vs. standard of care) - Outlining where we are and what's next – important learnings to date and perspectives on future directions
 Frank Nestle Global Head, Immunology Therapeutic Research Area & CSO North America Sanofi	9.15 Precision Dermatology: Targeting Atopic Disease & Beyond - Understanding how new technologies drive insights into molecular disease mechanisms and innovative therapies - Exploring atopic disease as the next frontier in inflammatory disease - Addressing the future landscape of Precision Dermatology
Latest Advances in Dermatology Translational Research	
 Jean-Philippe Therrien VP, Skin Biology EnDev Laboratories, Tergus Pharma	9.45 Understanding the Advantages & Limitations of Ex Vivo/In Vitro Human Skin Target Engagement Models - Addressing the misconception that human ex vivo skin models for target engagement will help to predict clinical efficacy – even though these models recapitulate major signalling pathways involved in the pathogenesis of the disease, they don't necessary recapitulate all of them - Understanding the purpose of these models, which is to help select: - The API and/or formulations that will lead to the best activity for their respective target(s) based on the API release from the formulation - The API delivery/pharmacokinetic into skin layers - Its activity/bioavailability
10.15 Speed Networking Session	
10.45 Morning Refreshments	
 Kim D. Kjeller Executive VP, Global R&D LEO Pharma A/S	11.15 From Serendipity to Precision Medicine - Establishing deep disease pathways understanding as a prerequisite vs. “designer drugs” approaches - Translating pathway targets to precise human efficacy - Tackling practicalities – right first time: - GDPR – creating the optimal informed consent - Minimal invasive methods to harvest biologic material - Machine learning vs. hypothesis testing - Precision Medicines – payer acceptance



Michael Howell
Senior Director
– Translational
Research
Incyte Corporation

11.45 Translational Approaches to Personalized Medicine in Dermatology

- Using Omics approaches to understand disease heterogeneity and pathogenesis
- Integrating precision medicine approaches in clinical trials
- Defining innovative approaches to predictive medicine



Venkat Reddy
Senior VP & Global
Head of Translational
Sciences
**Glenmark
Pharmaceuticals**

12.15 GBR830 – A Novel OX40 Antagonistic mAb Inducing Progressive & Sustained Improvement in Moderate to Severe Atopic Dermatitis Skin & Inflammatory Biomarkers as well as Disease Activity

- Detailing on how GBR 830 is a safe and well tolerated mAb, with a similar TEAE profile to placebo
- Inhibiting the OX40/OX40L pathway, as shown through reduced expression of OX40 and OX40L in lesional skin
- Reducing epidermal hyperplasia, and lesional biomarkers of disease activity with GBR 830
- Inducing clinical improvement in AD scores

12.45 Lunch & Networking

Enhancing Preclinical Development in Dermatology



Edward Hsia
VP, External Research
& Innovation
Almirall

1.45 Finding New Targets & Molecules: An Overview from an External Innovation Perspective

- Addressing external innovation as the key to sustainability of R&D
- Harnessing innovation at different stages of development with different external innovation models
- Understanding how academic collaborations are a key source of innovation



Lee Koetzner
Senior Manager,
Preclinical
Pharmacology
**Castle Creek
Pharmaceuticals**

2.15 Melanocortin Therapeutics for Rare & Prevalent Diseases

- Understanding how melanocortin receptor biology offers unique therapeutic opportunities
- Demonstrating utility in erythropoietic protoporphyria with a MC1R agonist
- Analyzing how melanocortin interventions may offer benefit in both rare and prevalent diseases



Paul Smith
Senior Director
– Preclinical
Pharmacology
Incyte Corporation

2.45 Integrative Preclinical Research Strategies to Identify New Therapeutic Opportunities in Dermatology

- Highlighting potential *in vivo/ex vivo/in vitro* skin models
- Exploring preclinical strategies to de-risk dermatology drug development
- Highlighting case studies that transitioned from preclinical research to clinical trial development

Developments in Topical Drug Development & Formulation Approaches



Jon Lenn
Senior VP, US
Operations
MedPharm

3.15 Advances in Dermatology Development – Systems & Models for Topicals

- Analyzing historical topical product development and its limitations
- Delving into the use of Performance Testing in topical product development – exploring old and new Performance Testing Systems and Models
- Describing a multimodal approach for de-risking development

3.45 Afternoon Refreshments & Networking

 Hans Hofland VP – Research & Nonclinical Development Dermira	4.15 De-risking Topical Product Development • Selecting the best molecules for topical delivery • Developing and selecting the best topical formulation • De-risking clinical development
 Conrad Winters Director, Product Development CPL	4.45 Continuous Manufacturing Approach for a Topical Formulation • Sharing data on a feasibility study for the manufacture of a challenging topical formulation prepared by hot melt extrusion • Exploring how this approach provides for batch flexibility and maximizing yields while producing a comparable formulation to conventional batch processing
 Samir Mitragotri Hiller Professor of Bioengineering & Hansjorg Wyss Professor of Biologically Inspired Engineering Harvard University	4.55 Overviewing the Latest Developments in Strategies for Topical Drug Delivery • Exploring challenges in topical drug delivery • Describing recent technological advances that have enabled delivery of small and large molecules into skin • Reviewing the current status and future potential of new strategies for topical drug delivery
 Weston Daniel Senior Director – Program Manager Exicure Inc.	5.25 SNA-Based Therapeutics to Treat Diseases with Great Unmet Medical Need • Assessing the drug discovery and development efforts by Exicure, revolving around the use of spherical nucleic acid (SNA) constructs • Exploring the distinct skin penetration properties and increased cellular uptake of SNAs • Developing XCUR17 (a topical antisense oligonucleotide in the SNA format), which is targeted to interleukin 17 receptor alpha mRNA for the treatment of chronic plaque psoriasis • Analyzing recent Phase 1 clinical data from XCUR17
	5.55 Chair's Closing Remarks

💧 All of the speakers did a great job. This was really a good conference – both size-wise and the quality of attendees 💧
Immune Pharmaceuticals

Conference Day Two | Thursday, November 29, 2018

8.15 Chair's Opening Remarks

The Current Landscape in Dermatology Drug Development



Kendall Marcus
Director, Division
of Dermatology &
Dental Products
FDA

8.30 Product Development in Atopic Dermatitis & Alopecia Areata

- Demonstrating efficacy in atopic dermatitis and alopecia areata
- Addressing Patient Reported Outcomes
- Exploring the size of safety databases needed to support marketing applications

9.00 Dedicated Q&A Session - Regulatory Perspectives



Dogan Fidan
Galderma



Jasmina Jankicevic



Mandeep Kaur
Sanofi



Paul Lizzul
Sienna
Biopharmaceuticals

9.15 Panel Discussion: The Evolving Clinical, Regulatory & Commercial Paradigm in Dermatology

- Exploring how to overcome key challenges in dermatology clinical development
- Assessing the need for cooperation between regulators, payers and drug developers in the definition of appropriate endpoints in the development of therapies targeting rare diseases
- Supporting value-based evidence to external stakeholders – establishing the value of new therapies and effectively demonstrating improved outcomes
- Navigating the challenges of a crowded development space



Dogan Fidan
Head of Global
Strategic Franchise
Immunology &
Inflammation
Galderma

9.45 Tackling Commercial Hurdles in Dermatology

- Addressing the changing market dynamics in the dermatology space
- Discussing reimbursement and market access perspectives on drug development for moderate to severe conditions, rare diseases, and biologic therapies
- Generating value – navigating through the competition

Advancing the Clinical Development of Dermatological Therapeutics



Dan Piacquadio
President, CEO &
Founder
Therapeutics Inc.

10.15 Fail Early, But Try Not to Fail Often

- Going from product concept to approval – avoiding CMC, nonclinical, clinical, regulatory and other failure potholes
- Understanding how success vs. failure is a team responsibility
- Sharing the risk – partnering of an asset as a failure mitigation strategy

10.45 Morning Refreshments & Networking



Paul Lizzul
CMO
Sienna
Biopharmaceuticals

11.15 Bridging the Innovation Gap in the Treatment of Mild to Moderate Dermatological Diseases

- Addressing the unmet need in topical drug development towards a large patient population with mild to moderate dermatological diseases, still primarily using topical steroids
- Updating on Sienna's TBD ("Topical by Design") approach, targeting key immune targets of psoriasis, atopic dermatitis, and pruritus
- Exploring early stage clinical data on SNA-125 (JAK3 inhibitor), in patients with AD and pruritus



James Cassella
Chief Development
Officer
**Concert
Pharmaceuticals**

11.45 CTP-543: Development of a Selective Janus Kinase (JAK) Inhibitor for the Treatment of Alopecia Areata

- Exploring alopecia Areata (AA), a common autoimmune disorder causing partial or widespread loss of hair on the scalp and/or body
- Discussing therapies targeting downstream JAK effectors – these have shown efficacy in autoimmune disorders such as AA, atopic dermatitis, and psoriasis
- Analyzing how CTP-543, a deuterium-modified analogue of ruxolitinib, is a selective JAK1/JAK2 inhibitor found to reverse AA hair loss in a small clinical study
- Presenting data from the early studies: CTP-543 is in Phase 2 clinical testing in patients with moderate to severe AA



12.15 Mastermind Session: Supporting the Successful Development & Commercialization of Dermatology Medicines

This session facilitates in-depth discussions among participants in an informal environment. After splitting into groups, participants will discuss key issues and challenges regarding the current landscape of dermatology drug development.

12.45 Lunch & Networking



John Zibert
Medical Director &
CMO
LEO Innovation Lab

1.45 Digitization of Dermatology - Is It Happening?

- Walking through digital patient tools in dermatology
- Exploring telemedicine and the fit in dermatology
- Delving into real-world evidence gathered from digital tools
- Digitalizing clinical trials in dermatology



Mary Spellman
CMO
**Menlo Therapeutics
Inc**

2.15 Selectively Repurposing an NK1 Receptor Antagonist

- Discovering and re-evaluating a shelved drug with noncomputational methods is viable for new dermatologic indications
- Assessing how current unmet medical needs may be met with this antidote to the typical drug development process

2.45 Afternoon Refreshments & Networking



Frédérique Menzaghi
Senior VP, R&D
**Cara Therapeutics,
Inc.**

3.15 Clinically Meaningful Reduction of Itch & Improvement in Quality of Life – Where Are We?

- Detailing on the importance of addressing itch and patient expectation
- Understanding what is a clinically meaningful change
- Getting regulatory consensus on endpoints: “itch is itch”...really?
- Validating Patient Reported Outcomes
- Reviewing a case report: Chronic-kidney disease-associated pruritus



Iain Stuart
Senior VP, R&D
**Foamix
Pharmaceuticals,
Inc.**

3.45 Clinical Development in Dermatology – Notes from an Emerging Specialty Pharmaceutical Company

- Exploring protocol development – striking the right balance between enrolment productivity and variable control
- How to successfully operationalize large clinical programs with limited internal resources
- Defining strategies for maintaining clinical site engagement and assessor “calibration”
- Outlining meaningful metrics in clinical research
- What to (and what not to) outsource?

4.15 Chair’s Closing Remarks

Pre-Conference Workshops

Tuesday, November 27, 2018

Workshop A

Innovative Approaches to Early Clinical Development & Dose-Finding: Integration of Dermal Pharmacokinetics (PK) & Pharmacodynamics (PD) in Dermal Drug Development

8.30am – 11.30am

One of the biggest challenges in dermatological research today remains the development of meaningful methodologies to determine the rate and extent to which topically or systemically applied drugs reaches its site of action and engages its target in the skin.

In this workshop learn how to make the most of early clinical development by integrating advances in techniques to quantitate dermal PK and PD measurements in model and patient settings and their role in dose finding.

Key topics to be discussed include:

- Challenges with dermal PK - did the API reach the site of action? - stratum corneum (tape-stripping), epidermis (raman spectroscopy), dermis (open flow microperfusion), transdermal (systemic absorption)
- Challenge models in healthy volunteers - imiquimod, wound healing after skin punch biopsies, lipopolysaccharide intradermal and intravenous, UVB irradiation, histamine, capsaicin

- Models in patients - psoriasis, atopic dermatitis / contact dermatitis, wound healing in ulcers and atopic dermatitis, hidradenitis suppurativa, vitiligo, acne
- The role of samples - biopsy, skin surface, non-invasive sampling (dry blood spot, swabs)
- Dose response relationship: Intended vs. unintended effects
- Toolbox - biochemistry, next generation biophysical measurements, non-invasive imaging, clinical assessments, lipidomics, patient reported assessments, mobile apps

Join us in this interactive session that will bring **practical insights into the inclusion of PK and PD measurements and clinical models** in early clinical development programs and how these can provide value and **de-risk clinical development of dermatological drugs**.



Betsy Hughes-Formella

Independent Consultant
Dermatology Drug Development



Robert Rissmann

Research Director Dermatology
Center for Human Drug Research

💧 I liked the speed networking session, the mix of people at the conference and the size – it was intimate and you get to know people well 💧

Realm Therapeutics Inc.

Pre-Conference Workshops

Tuesday, November 27, 2018

Workshop B

Innovating Drug Delivery & Formulation of Dermatological Drugs

12.00pm – 3.00pm

A key area of focus for drug developers working in dermatology is to ensure the optimization of drug delivery platforms and formulation approaches. In this workshop, you will have the opportunity to gain in-depth insights from leading experts in this space that will help you advance your topical development.

Key topics to be discussed include:

- **Skin Biology** – development strategy of topical formulations using skin biology tools, early safety screening, drug delivery and early DMPK, drug activity and target engagement models
- **Formulation Development** – formulation paradigm for topical drug development, skin delivery-pragmatic approaches for skin permeation enhancement, impact of formulations on performance and safety, linking innovation with clinical de-risking, generics (BA/BE waiver approaches)
- **Analytical Research and Development** – phase specific method development, differences in development tactics for new chemical entities versus known molecules, approaches to using excipient compatibility studies and other tools to predict product stability, challenges with development of topical specific extraction procedures, phase appropriate validation in support of clinical development stages, tech transfer streamlining and challenges
- **Manufacturing Process Development** – scale up and commercialization, quality by Design (QbD), novel packaging approaches, phase appropriate Clinical Trial Material (CTM), Scale Up and Post Approval Changes (SUPAC)

Join this interactive and comprehensive session that will allow you to **streamline and boost innovative delivery and formulation approaches** that match the potential of your drug candidates.



Vijendra Nalamothu
CEO
Tergus Pharma



Jean-Philippe Therrien
VP, Skin Biology
EnDev Laboratories, Tergus Pharma

💧 Meeting was well organized. Content was very rich. Networking was excellent 💧

BASF Pharma Solutions

Pre-Conference Workshops

Tuesday, November 27, 2018

Workshop C

Patient-Centricity Know-How – For Perpetual Innovation, Optimized Development & Successful Commercialization of Dermatologic Drugs

3.30pm – 6.30pm

Pharma/biotech companies in dermatology and medical esthetics will maximize the value of development programs and prevent multiple missteps with significant financial ramifications when genuine paradigm shift from product-centricity to patient-centricity finally occurs. The paradigm shift is already happening within regulatory agencies, among healthcare industry stakeholders, in scientific journals and at medical conferences.

This workshop is your opportunity to gain:

- Systematic knowledge of current patient-centric strategies and tools in drug development and commercialization
- Actionable insights from instructive patient engagement case studies

Key topics being addressed include:

- Patient-focused innovation incubators
- Patients' perspectives built into the foundation of product strategy
- Impact of the patient involvement on clinical development:
 - » Making the study design more relevant and clinical trial more feasible

- » Endpoints that make sense and will make a difference
- » Getting study completed with time and budget savings
- » Data interpretation that speaks value for the patient
- » Assets for regulatory approval
- Putting patients at the center of the medical affairs and commercial strategy
- Influence of patient preferences on decisions of healthcare stakeholders including payers and providers
- Overcoming barriers to increased patient involvement in clinical/medical/commercial decisions including tight deadlines, limited resources, compliance/regulations, flawed methodologies, and organizational resistance.

This interactive session, packed with relevant content and crisp-clear takeaways, will enable you to stimulate innovation in your organization, **maximize the value of your development programs and see ROI for patient engagement.**



Jasmina Jankicevic

Dermatologist, Clinical Development & Medical Affairs Consulting

Register by September 21 to save up to \$500!

Who Will You Meet?

Join Your Peers:

- Learn about the **latest developments and advances** from leading experts and innovators in dermatology
- Share your learnings and perspectives with a **focused community of peers** actively involved in the dermatology field
- Gain insight** into how to innovate development approaches, accelerate the bringing to market of new drugs, and successfully establish yourself as a value generating organization in the dermatology space
- Contribute to a **collaborative discussion** that will help you successfully navigate the current dermatology drug development landscape


7+ Hours of Dedicated Networking

3 Interactive Discussion Sessions

20+ Insightful Presentations By Field Experts


3 Focused In-Depth Pre-Conference Workshops

2017 Audience by Organization*



* Expected audience based on previous attendance

2017 Audience by Seniority*



* Expected audience based on previous attendance

Companies Who Have Previously Attended



Partners



Expertise Partner

MedPharm is the world leading specialist pharmaceutical development company,

committed to the creation and development of bespoke topical and transdermal formulations for application to the skin, nail, mucous membranes, eye, nose and lung. Alongside developing its own patented dermal drug delivery technologies, MedPharm uses its experience to support customers through regulatory approval previously resulting in biowaivers for generic submissions from regulatory authorities and marketing authorisations for over 60 products in the US and Europe.

www.medpharm.com



Expertise Partner

Tergus is a full-service topical pharmaceutical research,

development, testing and manufacturing company. The company is an industry leader for more than 20 years with a state-of-the-art facility in Durham, North Carolina. The company has a long and stellar reputation for delivering quality and results for clients from formulation through manufacturing, which is why people say, "Think Topical. Think Tergus"

www.terguspharma.com



Innovation Partner

CPL is a leading contract development and manufacturing

organization providing product development and commercial manufacturing of non-sterile liquid and semisolid pharmaceutical and regulated OTC products. Our facilities are registered by FDA and Health Canada and maintain an outstanding record of regulatory compliance. CPL is a reputable contract manufacturer known to provide high quality product with exceptional service. By offering a full-spectrum partnership – from development to commercial production – CPL creates strategic, long-term relationships with our customers.

www.cplltd.com



Expertise Partner

San Diego based, Therapeutics, Inc., The Dermatology CRO was founded in 1997. Approximately 90%

of our activities are focused on developing dermatology products. TI is the only dermatology-focused CRO that provides all services required to move a product concept through non-clinical and clinical stages to FDA approval. During the last 5 years: TI managed >11,000 subjects in >90 clinical studies and filed >20 INDs and IDEs in a variety of drug, device and biologic programs.

www.therapeuticsinc.com



Exhibitor

DPT, a Mylan company, is a leading contract development and manufacturing organization,

recognized for its excellence in semi-solid and liquid dosage forms. Backed by a team of approximately 1,000 employees in San Antonio, Texas, DPT has unmatched experience, resources and capacity to efficiently serve your pharmaceutical development and manufacturing needs – no matter the scope. From concept to commercialization, DPT remains committed to exceeding expectations for quality and service.

www.dptlabs.com



Exhibitor

Dow Development Lab's core expertise is in the design,

development and manufacture of topical drug products for dermatology. The formulation, analytical, production, quality, and clinical labeling groups have decades of experience moving products quickly toward regulatory approval. Always with the patient in mind, products are designed to be disease-compatible and cosmetically elegant. Dow Development Labs works seamlessly with its parent company Symbio, a specialty clinical CRO, to rapidly advance client dermatological programs through all stages of clinical development.

www.dowdevelopmentlabs.com



Event Partner

Bioskin is a leading CRO with unique understanding and

capabilities for both early and late phase dermatological clinical trials. Recognized by global companies as a valuable partner in studies for drugs, medical devices, food supplements and advanced cosmetics since 1992, bioskin offers early phase safety and Proof-of-Concept studies, vasoconstrictor assays according to FDA guideline, global Phase II – IV trials for NCEs, new formulations with known actives as well as consulting in the field of dermatology.

www.bioskinCRO.com

For more information about partnership opportunities or to become a partner, contact:



Jennifer Mackay

Partnerships Director

T. +1 617 455 4188

E. sponsor@hansonwade.com

Ready to Register?

3 Easy Ways To Book



www.dermatology-drugdevelopment.com/register



Tel: +1 617 455 4188



Email: register@hansonwade.com



Team Discounts*

- 10% discount – 3 delegates
- 15% discount – 4 delegates
- 20% discount – 5 or more delegates


*Please note that discounts are only valid when three or more delegates from one company book and pay at the same time. Contact: register@hansonwade.com

Secure Your Place

Industry Pricing	Register & Pay before Friday September 21, 2018	Standard Pricing
Platinum: Conference & 3 Workshops	\$4396 (save \$500)	\$4596 (save \$300)
Gold: Conference & 2 Workshops	\$3797 (save \$400)	\$3997 (Save \$200)
Silver: Conference & 1 Workshop	\$3198 (save \$300)	\$3398 (Save \$100)
Bronze: Conference Only	\$2599 (save \$200)	\$2799
Workshops - Each	\$699	

Academic/ Start-up Pricing*	Register & Pay before Friday September 21, 2018	Standard Pricing
Platinum: Conference & 3 Workshops	\$2496 (save \$500)	\$2696 (save \$300)
Gold: Conference & 2 Workshops	\$2197 (save \$400)	\$2397 (Save \$200)
Silver: Conference & 1 Workshop	\$1898 (save \$300)	\$2098 (Save \$100)
Bronze: Conference Only	\$1599 (save \$200)	\$1799
Workshops - Each	\$399	

*T&Cs Apply: Start-up rate is subject to organizer approval. Please visit the event website for more details.



Venue

Hyatt Regency Boston
One Avenue de Lafayette
Boston, Massachusetts, USA, 02111

For further information or assistance, please visit
www.hyatt.com

TERMS & CONDITIONS

Full payment is due on registration. Cancellation and Substitution Policy: Cancellations must be received in writing. If the cancellation is received more than 14 days before the conference attendees will receive a full credit to a future conference. Cancellations received 14 days or less (including the fourteenth day) prior to the conference will be liable for the full fee. A substitution from the same organization can be made at any time.

Changes to Conference & Agenda: Hanson Wade reserves the right to postpone or cancel an event, to change the location or alter the advertised speakers. Hanson Wade is not responsible for any loss or damage or costs incurred as a result of substitution, alteration, postponement or cancellation of an event for any reason and including causes beyond its control including without limitation, acts of God, natural disasters, sabotage, accident, trade or industrial disputes, terrorism or hostilities.

Data Protection: The personal information shown and/or provided by you will be held in a database. It may be used to keep you up to date with developments in your industry. Sometimes your details may be obtained or made available to third parties for marketing purposes. If you do not wish your details to be used for this purpose, please write to: Database Manager, Hanson Wade, Suite A, 6 Honduras Street, London EC1Y 0TH